Lifitegrast
- Generic Name
- Lifitegrast
- Brand Names
- Xiidra
- Drug Type
- Small Molecule
- Chemical Formula
- C29H24Cl2N2O7S
- CAS Number
- 1025967-78-5
- Unique Ingredient Identifier
- 038E5L962W
- Background
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown ...
- Indication
适用于治疗干眼病（DED）的症状和体征。
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- -
Dry Eye Syndrome Treatment (Evaporative, Aqueous Deficient)
The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen time. OTC products lead, with prescription therapies underutilized. Market challenges include product tolerability issues and regulatory hurdles. Innovations and strategic initiatives by key players, like the FDA approval of Tyrvaya nasal spray, are boosting the market. North America leads due to high disease prevalence and treatment awareness.
Dry Eye Syndrome Treatment (Evaporative, Aqueous Deficient) Market Trends
The Dry Eye Syndrome Treatment Market is projected to reach USD 10.13 billion by 2030, driven by increased screen use, aging population, and eye disease prevalence. Evaporative dry eye syndrome dominates due to high screen exposure. OTC products lead, with only 10% on prescription therapies. Innovations and new product launches by key players like Novartis, AbbVie, and Oyster Point Pharma are boosting the market.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath